Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is thought that vWF can extend the half-life of FVIII”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Zerra et al., 2020
In the citing paper
“perhaps altered glycosylation of FVIII itself can alter its half-life or interaction with the immune system in general”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Zerra et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the immune system in the spleen
Lewis, S. M., Williams, A., & Eisenbarth, S. C. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau6085 · Cited by 1,301 · cited 1×
“As each APC population can expresss distinct FcγRs or complement receptors (95, 96), the relative engagement of each antibody effector system is possibly dicated by the APC predominately responsible for T cell activation in vivo.”
BackgroundThe complement system in regulation of adaptive immunity
Carroll, M. C. (2004) · Nature Immunology · doi:10.1038/ni1113 · Cited by 1,035
Wessels, M. R., Butko, P., Ma, M., Warren, H. B., Lage, A. L., & Carroll, M. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11490 · Cited by 503
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Parvathaneni, K., & Scott, D. W. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018556 · Cited by 56
Herzog, R. W., Kuteyeva, V., Saboungi, R., Terhorst, C., & Biswas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00274 · Cited by 24
Research works printed but not linked: 98
- Kulkarni, 2011, Pediatric hemophilia: a review, Semin Thromb Hemost., 37, 737, 10.1055/s-0031-1297164 · doi:10.1055/s-0031-1297164
- Zimmerman, 2013, Hemophilia: in review, Pediatr Rev., 34, 289, 10.1542/pir.34-7-289 · DOI
- Ehrenforth, 1992, Factor VIII inhibitors in haemophiliacs, Lancet., 340, 253, 10.1016/0140-6736(92)90530-G · doi:10.1016/0140-6736(92)90530-g
- Ehrenforth, 1992, Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs, Lancet., 339, 594, 10.1016/0140-6736(92)90874-3 · DOI · Paper page
- Aledort, 2004, Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity, J Thromb Haemost., 2, 1700, 10.1111/j.1538-7836.2004.00944.x · DOI · Paper page
- Lollar, 2004, Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX, J Thromb Haemost., 2, 1082, 10.1111/j.1538-7836.2004.00802.x · DOI
- Meeks, 2007, Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation, Blood., 110, 4234, 10.1182/blood-2007-06-096842 · DOI
- Kempton, 2014, Toward optimal therapy for inhibitors in hemophilia, Blood., 124, 3365, 10.1182/blood-2014-05-577643 · DOI
- Kempton, 2009, How we treat a hemophilia A patient with a factor VIII inhibitor, Blood., 113, 11, 10.1182/blood-2008-06-160432 · DOI · Paper page
- Lorenzo, 2001, Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age, Br J Haematol., 113, 600, 10.1046/j.1365-2141.2001.02828.x · DOI · Paper page
- White, 2005, Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?, J Thromb Haemost., 3, 1676, 10.1111/j.1538-7836.2005.01375.x · DOI
- Lillicrap, 2006, The role of immunomodulation in the management of factor VIII inhibitors, Hematology Am Soc Hematol Educ Program., 2006, 421, 10.1182/asheducation-2006.1.421 · doi:10.1182/asheducation-2006.1.421
- Di Michele, 2011, Immune tolerance induction in haemophilia: evidence and the way forward, J Thromb Haemost., 9, 216, 10.1111/j.1538-7836.2011.04349.x · DOI
- Moorehead, 2015, Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor, J Pediatr Hematol Oncol., 37, e220, 10.1097/MPH.0000000000000287 · doi:10.1097/mph.0000000000000287
- Valentino, 2015, US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors, Haemophilia., 21, 559, 10.1111/hae.12730 · DOI
- Aledort, 2019, Factor VIII replacement is still the standard of care in haemophilia A, Blood Transfus., 17, 479, 10.2450/2019.0211-19 · DOI
- Rodriguez-Merchan, 2019, Emicizumab: review of the literature and critical appraisal, Haemophilia., 25, 11, 10.1111/hae.13641 · DOI
- Yada, 2019, Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations, J Blood Med., 10, 171, 10.2147/JBM.S175952 · DOI
- Navarrete, 2009, Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A, J Thromb Haemost., 7, 1816, 10.1111/j.1538-7836.2009.03571.x · DOI
- Zerra, 2017, Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A, Blood., 130, 2559, 10.1182/blood-2017-05-782912 · DOI
- Ettinger, 2009, Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses, Blood., 114, 1423, 10.1182/blood-2009-01-200725 · DOI · Paper page
- Gupta, 2015, Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance, Sci Transl Med., 7, 275ra221, 10.1126/scitranslmed.aaa1957 · DOI
- Kim, 2015, Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses, Blood., 125, 1107, 10.1182/blood-2014-04-566786 · DOI · Paper page
- Biswas, 2017, Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin, Thromb Haemost., 117, 33, 10.1160/TH16-05-0404 · DOI
- Rayes, 2018, Complement C3 is a novel modulator of the anti-factor VIII immune response, Haematologica., 103, 351, 10.3324/haematol.2017.165720 · doi:10.3324/haematol.2017.165720
- Jing, 2019, Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice, Blood Adv., 3, 3099, 10.1182/bloodadvances.2019000650 · DOI
- Janeway, 1989, Approaching the asymptote? Evolution and revolution in immunology, Cold Spring Harb Symp Quant Biol., 54, 1, 10.1101/SQB.1989.054.01.003 · DOI · Paper page
- Aderem, 2000, Toll-like receptors in the induction of the innate immune response, Nature., 406, 782, 10.1038/35021228 · DOI · Paper page
- Medzhitov, 2000, Innate immune recognition: mechanisms and pathways, Immunol Rev., 173, 89, 10.1034/j.1600-065X.2000.917309.x · DOI · Paper page
- Gallucci, 2001, Danger signals: SOS to the immune system, Curr Opin Immunol., 13, 114, 10.1016/S0952-7915(00)00191-6 · DOI · Paper page
- Matzinger, 2002, The danger model: a renewed sense of self, Science., 296, 301, 10.1126/science.1071059 · DOI · Paper page
- O'Hagan, 2003, Recent advances in the discovery and delivery of vaccine adjuvants, Nat Rev Drug Discov., 2, 727, 10.1038/nrd1176 · DOI · Paper page
- Takeda, 2003, Toll-like receptors, Annu Rev Immunol., 21, 335, 10.1146/annurev.immunol.21.120601.141126 · DOI · Paper page
- Erlandsson Harris, 2004, Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator, Eur J Immunol., 34, 1503, 10.1002/eji.200424916 · DOI · Paper page
- Zhang, 2011, Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice, Blood., 117, 2223, 10.1182/blood-2010-06-293324 · DOI
- Meeks, 2012, A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function, Blood., 120, 2512, 10.1182/blood-2012-02-412361 · DOI
- Chao, 2016, Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene, J Thromb Haemost., 14, 346, 10.1111/jth.13202 · DOI
- Hartholt, 2017, Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells, J Thromb Haemost., 15, 329, 10.1111/jth.13570 · doi:10.1111/jth.13570
- Vollack, 2017, Anti-FcgammaRIIB (CD32) antibodies differentially modulate murine FVIII-specific recall response in vitro, Scand J Immunol., 86, 91, 10.1111/sji.12573 · doi:10.1111/sji.12573
- Batsuli, 2018, Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model, J Thromb Haemost., 16, 1779, 10.1111/jth.14233 · DOI
- Nimmerjahn, 2006, Fcgamma receptors: old friends and new family members, Immunity., 24, 19, 10.1016/j.immuni.2005.11.010 · DOI · Paper page
- Yada, 2003, Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake, Cell Immunol., 225, 21, 10.1016/j.cellimm.2003.09.008 · DOI
- Liu, 2016, Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice, Blood., 128, 3159, 10.1182/blood-2016-06-724732 · DOI
- Stowell, 2013, Antigen modulation confers protection to red blood cells from antibody through Fcgamma receptor ligation, J Immunol., 191, 5013, 10.4049/jimmunol.1300885 · DOI
- Mener, 2018, Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses, JCI Insight., 3, e121631, 10.1172/jci.insight.121631 · DOI
- Kasper, 1975, Proceedings: A more uniform measurement of factor VIII inhibitors, Thromb Diath Haemorrh., 34, 612, 10.1055/s-0039-1689482 · DOI · Paper page
- Stowell, 2013, Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model, Blood., 122, 1494, 10.1182/blood-2013-03-488874 · DOI
- Stowell, 2014, Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies, Transfusion., 54, 179, 10.1111/trf.12217 · doi:10.1111/trf.12217
- Girard-Pierce, 2013, A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation, Blood., 122, 1793, 10.1182/blood-2013-06-508952 · doi:10.1182/blood-2013-06-508952
- Patel, 2018, Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion, Front Immunol., 9, 2516, 10.3389/fimmu.2018.02516 · DOI
- Sarma, 2011, The complement system, Cell Tissue Res., 343, 227, 10.1007/s00441-010-1034-0 · DOI · Paper page
- You, 2011, Marginal zone B cells regulate antigen capture by marginal zone macrophages, J Immunol, 186, 2172, 10.4049/jimmunol.1002106 · DOI · Paper page
- Seiler, 1997, Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection, Eur J Immunol., 27, 2626, 10.1002/eji.1830271023 · DOI · Paper page
- Aichele, 2003, Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses, J Immunol., 171, 1148, 10.4049/jimmunol.171.3.1148 · DOI · Paper page
- Malkiel, 2009, The loss and gain of marginal zone and peritoneal B cells is different in response to relapsing fever and Lyme disease Borrelia, J Immunol., 182, 498, 10.4049/jimmunol.182.1.498 · doi:10.4049/jimmunol.182.1.498
- Attanavanich, 2004, Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells, J Immunol., 172, 803, 10.4049/jimmunol.172.2.803 · DOI · Paper page
- Cerutti, 2013, Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes, Nat Rev Immunol., 13, 118, 10.1038/nri3383 · DOI · Paper page
- Martin, 2002, Marginal-zone B cells, Nat Rev Immunol., 2, 323, 10.1038/nri799 · DOI · Paper page
- Cinamon, 2008, Follicular shuttling of marginal zone B cells facilitates antigen transport, Nat Immunol., 9, 54, 10.1038/ni1542 · DOI · Paper page
- Snapper, 1993, Comparative in vitro analysis of proliferation, Ig secretion, and Ig class switching by murine marginal zone and follicular B cells, J Immunol., 150, 2737, 10.4049/jimmunol.150.7.2737 · DOI
- Heyman, 1990, The immune complex: possible ways of regulating the antibody response, Immunol Today., 11, 310, 10.1016/0167-5699(90)90126-T · doi:10.1016/0167-5699(90)90126-t
- Heyman, 2000, Regulation of antibody responses via antibodies, complement, and Fc receptors, Annu Rev Immunol., 18, 709, 10.1146/annurev.immunol.18.1.709 · DOI · Paper page
- Jancar, 2005, Immune complex-mediated tissue injury: a multistep paradigm, Trends Immunol., 26, 48, 10.1016/j.it.2004.11.007 · DOI
- Nimmerjahn, 2008, Fcgamma receptors as regulators of immune responses, Nat Rev Immunol., 8, 34, 10.1038/nri2206 · DOI · Paper page
- Ahearn, 1996, Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen, Immunity., 4, 251, 10.1016/S1074-7613(00)80433-1 · DOI · Paper page
- Fischer, 1998, Dependence of germinal center B cells on expression of CD21/CD35 for survival, Science., 280, 582, 10.1126/science.280.5363.582 · DOI · Paper page
- Da Costa, 1999, Humoral response to herpes simplex virus is complement-dependent, Proc Natl Acad Sci USA., 96, 12708, 10.1073/pnas.96.22.12708 · DOI · Paper page
- Carroll, 2012, Regulation of humoral immunity by complement, Immunity., 37, 199, 10.1016/j.immuni.2012.08.002 · DOI · Paper page
- Fischer, 1996, Regulation of the B cell response to T-dependent antigens by classical pathway complement, J Immunol., 157, 549, 10.4049/jimmunol.157.2.549 · DOI · Paper page
- Molina, 1996, Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2, Proc Natl Acad Sci USA., 93, 3357, 10.1073/pnas.93.8.3357 · DOI · Paper page
- Vogel, 2010, Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion, Toxicon., 56, 1198, 10.1016/j.toxicon.2010.04.007 · DOI · Paper page
- Samuels, 2019, Alternative complement pathway activation provokes a hypercoagulable state with diminished fibrinolysis, Shock., 53, 560, 10.1097/SHK.0000000000001437 · DOI
- Kock, 2004, Structure and function of recombinant cobra venom factor, J Biol Chem., 279, 30836, 10.1074/jbc.M403196200 · DOI
- Lambris, 1988, The multifunctional role of C3, the third component of complement, Immunol Today., 9, 387, 10.1016/0167-5699(88)91240-6 · DOI · Paper page
- Nordahl, 2004, Activation of the complement system generates antibacterial peptides, Proc Natl Acad Sci USA., 101, 16879, 10.1073/pnas.0406678101 · DOI · Paper page
- Kang, 2006, A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q, Cell., 125, 47, 10.1016/j.cell.2006.01.046 · DOI · Paper page
- Rittirsch, 2008, Functional roles for C5a receptors in sepsis, Nat Med., 14, 551, 10.1038/nm1753 · DOI · Paper page
- Ward, 2009, Functions of C5a receptors, J Mol Med., 87, 375, 10.1007/s00109-009-0442-7 · DOI · Paper page
- Ing, 2018, Absence of a neutralizing antibody response to humanized cobra venom factor in mice, Mol Immunol., 97, 1, 10.1016/j.molimm.2018.02.018 · doi:10.1016/j.molimm.2018.02.018
- Shushakova, 2002, C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease, J Clin Invest., 110, 1823, 10.1172/JCI16577 · DOI · Paper page
- Zaal, 2019, Differential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2, Immunol Lett., 209, 45, 10.1016/j.imlet.2019.03.014 · DOI
- Ricklin, 2010, Complement: a key system for immune surveillance and homeostasis, Nat Immunol., 11, 785, 10.1038/ni.1923 · DOI · Paper page
- Reis, 2019, New insights into the immune functions of complement, Nat Rev Immunol., 19, 503, 10.1038/s41577-019-0168-x · DOI · Paper page
- Valdez, 2014, Influence of the microbiota on vaccine effectiveness, Trends Immunol., 35, 526, 10.1016/j.it.2014.07.003 · DOI
- Lazar, 2018, Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer, Front Immunol., 9, 1830, 10.3389/fimmu.2018.01830 · DOI · Paper page
- Lai, 2016, Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A, Blood., 127, 3439, 10.1182/blood-2015-11-679282 · DOI
- Patel, 2018, Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice, Blood Adv., 2, 105, 10.1182/bloodadvances.2017010124 · DOI
- Stowell, 2012, Initiation and regulation of complement during hemolytic transfusion reactions, Clin Dev Immunol., 2012, 307093, 10.1155/2012/307093 · DOI
- Calabro, 2016, Bridging channel dendritic cells induce immunity to transfused red blood cells, J Exp Med., 213, 887, 10.1084/jem.20151720 · DOI
- Eisenbarth, 2019, Dendritic cell subsets in T cell programming: location dictates function, Nat Rev Immunol., 19, 89, 10.1038/s41577-018-0088-1 · DOI · Paper page
- Nickel, 2016, Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series, Transfusion., 56, 107, 10.1111/trf.13379 · DOI
- Chonat, 2018, Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease, Haematologica., 103, e483, 10.3324/haematol.2018.194670 · DOI
- Dean, 2018, Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease, Transfusion., 59, 448, 10.1111/trf.15010 · DOI
- Dean, 2019, Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients, Transfusion., 59, 1698, 10.1111/trf.15227 · doi:10.1111/trf.15227
- Meinderts, 2017, Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease, Blood., 130, 2121, 10.1182/blood-2017-05-784876 · DOI
- Li, 2019, Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 Risk in the HVTN 505 HIV vaccine trial, J Virol., 93, e02041, 10.1128/JVI.02041-18 · DOI
- Arthur, 2017, Antigen density dictates immune responsiveness following red blood cell transfusion, J Immunol., 198, 2671, 10.4049/jimmunol.1601736 · DOI
- Maier, 2018, Antibody-mediated immune suppression by antigen modulation is antigen-specific, Blood Adv., 2, 2986, 10.1182/bloodadvances.2018018408 · DOI
Cited by
Jajosky, R. P., Wu, S.-C., Zheng, L., Jajosky, A. N., Jajosky, P. G., Josephson, C. D., Hollenhorst, M. A., Sackstein, R., Cummings, R. D., Arthur, C. M., et al. (2023) · iScience · doi:10.1016/j.isci.2022.105798 · Cited by 110
Self-citation
Metadata
- Authors
- Zerra, P. E., Arthur, C. M., Chonat, S., Maier, C. L., Mener, A., Shin, S., Allen, J. W. L., Baldwin, W. H., Cox, C., Verkerke, H., Jajosky, R. P., Tormey, C. A., Meeks, S. L., & Stowell, S. R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-06-09
- Volume
- 11
- ISSN
- 1664-3224
- Cited by
- 18
- References
- 6
- Funders
- National Institutes of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation. https://app.cochat.ai/papers/10.3389/fimmu.2020.00905
- The paper
- Zerra, P. E., Arthur, C. M., Chonat, S., Maier, C. L., Mener, A., Shin, S., Allen, J. W. L., Baldwin, W. H., Cox, C., Verkerke, H., Jajosky, R. P., Tormey, C. A., Meeks, S. L., & Stowell, S. R. (2020). Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.00905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.